Trials / Completed
CompletedNCT05409586
Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis
Evaluating the Risk Factors and the Role of Albumin-to-globulin Ratio in Predicting Recurrence Among Patients With Idiopathic Granulomatous Mastitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 109 (actual)
- Sponsor
- Samsun Education and Research Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Albumin-to-globulin ratio (AGR) is an inflammation-based index that has been shown to have a role in many cancers and inflammatory diseases. Idiopathic granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with a high recurrence rate. As a relatively new biomarker for inflammatory diseases, AGR's role in IGM recurrence has never been investigated in the literature. This study primarily investigates the possible risk factors for IGM recurrence and whether AGR can be used as a predictive factor.
Detailed description
Patients diagnosed with IGM on pathology reports between January 2016 and March 2021 were enrolled in the study and their medical records were analyzed retrospectively. The patients were divided into two groups: recurrence and non-recurrence. Clinical, demographic characteristics, and laboratory parameters were compared. The best cut-off value for significant factors in predicting recurrence was determined by receiver operating characteristic (ROC) analysis. Univariate and multivariate logistic regression analysis was used to determine the risk factors that are effective in IGM recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | segmental mastectomy | The preferred method in the treatment of some patients diagnosed with IGM |
Timeline
- Start date
- 2022-04-20
- Primary completion
- 2022-05-20
- Completion
- 2022-05-25
- First posted
- 2022-06-08
- Last updated
- 2022-06-08
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT05409586. Inclusion in this directory is not an endorsement.